Canada Approves BMS’s Abecma (BCMA CAR-T) in ≥4L R/R MM; Will the Earliest Reimbursement Occur in 2022?
On Monday, May 31, BMS announced (press release) that Health Canada has granted conditional approval for Abecma (BCMA CAR-T) in ≥4L r/r MM, based on results from the Ph2 KarMMa trial. Below, Celltelligence provides insights on Abecma’s conditional approval in an earlier line of therapy compared to the US, while discussing when an earliest possible decision on reimbursement in Canada could occur.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.